Literature DB >> 12551982

The early expression of glycoprotein B from herpes simplex virus can be detected by antigen-specific CD8+ T cells.

Scott N Mueller1, Claerwen M Jones, Weisan Chen, Yoshihiro Kawaoka, Maria R Castrucci, William R Heath, Francis R Carbone.   

Abstract

The immune response to cutaneous herpes simplex virus type 1 (HSV-1) infection begins with remarkable rapidity. Activation of specific cytotoxic T lymphocytes (CTL) begins within hours of infection, even though the response within the draining lymph nodes peaks nearly 5 days later. HSV gene products are classified into three main groups, alpha, beta, and gamma, based on their kinetics and requirements for expression. In C57BL/6 mice, the immunodominant epitope from HSV is derived from glycoprotein B (gB(498-505)). While gB is considered a gamma or "late" gene product, previous reports have indicated that some level of gene expression may occur soon after infection. Using brefeldin A as a specific inhibitor of viral antigen presentation to major histocompatibility complex class I-restricted CTL, we have formally addressed the timing of gB peptide expression in an immunologically relevant manner following infection. Presentation of gB peptide detected by T-cell activation was first observed within 2 h of infection. Comparison with another viral epitope expressed early during infection, HSV-1 ribonucleotide reductase, demonstrated that gB is presented with the same kinetics as this classical early-gene product. Moreover, this rapidity of gB expression was further illustrated via rapid priming of naïve transgenic CD8(+) T cells in vivo after HSV-1 infection of mice. These results establish that gB is expressed rapidly following HSV-1 infection, at levels capable of effectively stimulating CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12551982      PMCID: PMC141123          DOI: 10.1128/jvi.77.4.2445-2451.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Intracellular rate-limiting steps in MHC class I antigen processing.

Authors:  M Montoya; M Del Val
Journal:  J Immunol       Date:  1999-08-15       Impact factor: 5.422

Review 2.  Regulation of herpes simplex virus type 1 gene expression.

Authors:  J Hay; W T Ruyechan
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

3.  Analysis of the gB promoter of herpes simplex virus type 1: high-level expression requires both an 89-base-pair promoter fragment and a nontranslated leader sequence.

Authors:  N E Pederson; S Person; F L Homa
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

Review 4.  The role of immune mechanisms in control of herpes simplex virus infection of the peripheral nervous system.

Authors:  A Simmons; D Tscharke; P Speck
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

5.  Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides.

Authors:  T Hanke; F L Graham; K L Rosenthal; D C Johnson
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

6.  Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression.

Authors:  I L Smith; M A Hardwicke; R M Sandri-Goldin
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

7.  Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes.

Authors:  J W Yewdell; J R Bennink
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

8.  Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum.

Authors:  J H Cox; J W Yewdell; L C Eisenlohr; P R Johnson; J R Bennink
Journal:  Science       Date:  1990-02-09       Impact factor: 47.728

9.  In vivo priming and activation of memory cytotoxic T-lymphocytes (CTL) by a chimeric simian virus 40 T antigen expressing an eight amino acid residue herpes simplex virus gB CTL epitope.

Authors:  R H Bonneau; T M Fu; S S Tevethia
Journal:  Virology       Date:  1993-12       Impact factor: 3.616

10.  Participation of a novel 88-kD protein in the biogenesis of murine class I histocompatibility molecules.

Authors:  E Degen; D B Williams
Journal:  J Cell Biol       Date:  1991-03       Impact factor: 10.539

View more
  21 in total

Review 1.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

2.  Delaying the expression of herpes simplex virus type 1 glycoprotein B (gB) to a true late gene alters neurovirulence and inhibits the gB-CD8+ T-cell response in the trigeminal ganglion.

Authors:  Srividya Ramachandran; Katherine A Davoli; Michael B Yee; Robert L Hendricks; Paul R Kinchington
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

3.  In vivo ablation of CD11c-positive dendritic cells increases susceptibility to herpes simplex virus type 1 infection and diminishes NK and T-cell responses.

Authors:  Sadik H Kassim; Naveen K Rajasagi; Xiangyi Zhao; Robert Chervenak; Stephen R Jennings
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

4.  A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.

Authors:  Flavia Chiuppesi; Laura Vannucci; Anna De Luca; Michele Lai; Barbara Matteoli; Giulia Freer; Roberto Manservigi; Luca Ceccherini-Nelli; Fabrizio Maggi; Mauro Bendinelli; Mauro Pistello
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

5.  Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia.

Authors:  Kamal M Khanna; Robert H Bonneau; Paul R Kinchington; Robert L Hendricks
Journal:  Immunity       Date:  2003-05       Impact factor: 31.745

6.  Development and pathogenic evaluation of recombinant herpes simplex virus type 1 expressing two fluorescent reporter genes from different lytic promoters.

Authors:  Srividya Ramachandran; Jared E Knickelbein; Christina Ferko; Robert L Hendricks; Paul R Kinchington
Journal:  Virology       Date:  2008-07-11       Impact factor: 3.616

7.  Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency.

Authors:  Jared E Knickelbein; Kamal M Khanna; Michael B Yee; Catherine J Baty; Paul R Kinchington; Robert L Hendricks
Journal:  Science       Date:  2008-10-10       Impact factor: 47.728

8.  Medroxyprogesterone acetate inhibits CD8+ T cell viral-specific effector function and induces herpes simplex virus type 1 reactivation.

Authors:  Thomas L Cherpes; James L Busch; Brian S Sheridan; Stephen A K Harvey; Robert L Hendricks
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

Review 9.  Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.

Authors:  Michael W Ferenczy
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

10.  Rapid host immune response and viral dynamics in herpes simplex virus-2 infection.

Authors:  Joshua T Schiffer; Lawrence Corey
Journal:  Nat Med       Date:  2013-03       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.